2024.May.02

Announcement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for Phase II human clinical trial

1.Date of occurrence of the event:2024/05/02 2.New drug name or code:OBI-858 Novel Botulinum Neurotoxin 3.Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. Patents for its special molecular weight have been granted in Taiwan, Australia, New Zealand, Japan and Russia. 4.Planned development stages: Phase II, III clinical […]

HOMEWhat’s NewAnnouncementsAnnouncement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for Phase II human clinical trial

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2024.Apr.25

Announcement of the Company’s board meeting date to approve 2024Q1 consolidated financial report

2024.May.10

Correct consolidated financial reports from 2023Q1 to Q4, independent 2024Q4 financial report, and iXBRL, which have no impact on income and losses and net assets.